From: breastadvocateapp.com
Researchers from Penn State University have developed a groundbreaking nanoparticle that could revolutionize breast cancer treatment. Dubbed the “GPS nanoparticle,” this innovative technology has shown promising results in targeting and combating hard-to-treat basal-like breast cancers.
Targeting Aggressive Breast Cancers
Basal-like breast cancers, akin to triple-negative breast cancers, pose significant challenges due to their aggressive nature and propensity for metastasis. Unlike other breast cancers, they lack specific therapeutic targets, making them difficult to treat.
Trojan Horse Approach
The GPS nanoparticle functions as a Trojan horse, disguised with specially designed fatty molecules resembling natural lipids. Loaded with CRISPR-Cas9 molecules, it can target specific genes implicated in cancer progression. In this study, the researchers targeted the FOXC1 gene, known for its role in promoting metastasis.
What sets this nanoparticle apart is its “zwitterionic” designer lipids, which remain neutral until they encounter the acidic environment of cancer cells. This ensures targeted payload release while minimizing off-target effects and immune responses.
Novel Targeting Strategy
To ensure precise targeting, the researchers attached an epithelial cell adhesion molecule (EpCAM) to the nanoparticle, known for its affinity to basal-like breast cancer cells. This strategy represents a novel approach in cancer treatment delivery systems.
Initial tests in human cell lines and mouse models have shown promising results, with the nanoparticle effectively delivering the CRISPR/Cas9 system to target cancer cells and suppress the FOXC1 gene.
Future Directions
The team’s next steps involve further refining the nanoparticle platform for potential clinical applications in humans. Beyond breast cancer, they see immense potential in customizing this technology for other therapeutic purposes.
This groundbreaking research offers hope for a more targeted and effective treatment approach for basal-like breast cancers, addressing an unmet clinical need and paving the way for innovative cancer therapies.
Funding and Collaboration
Funding for this study was provided by Penn State, the University of Maryland Baltimore School of Medicine, the Centers for Disease Control and Prevention, the U.S. National Science Foundation, and the U.S. Department of Defense Congressionally Directed Medical Research Program.
Stay informed and engaged with the latest advancements. Empower yourself with knowledge and make more informed decisions about your breast cancer treatment and care. Visit the Breast Advocate App website today and join us in the fight against breast cancer.
Barbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide.